Avanos Medical (NYSE:AVNS) Lowered to Strong Sell Rating by Zacks Research

Avanos Medical (NYSE:AVNS) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.24 EPS, FY2025 earnings at $0.89 EPS, Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $1.08 EPS, Q1 2027 earnings at $0.33 EPS, Q2 2027 earnings at $0.32 EPS, Q3 2027 earnings at $0.26 EPS and FY2027 earnings at $1.24 EPS.

AVNS has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d)” rating on shares of Avanos Medical in a research report on Monday. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Sell rating, According to MarketBeat.com, Avanos Medical currently has a consensus rating of “Sell”.

Avanos Medical Trading Up 0.7%

Avanos Medical stock opened at $11.43 on Monday. Avanos Medical has a 52 week low of $9.30 and a 52 week high of $19.29. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38. The firm has a market capitalization of $530.58 million, a price-to-earnings ratio of -1.12 and a beta of 1.09. The company has a 50 day moving average price of $11.46 and a 200 day moving average price of $11.78.

Avanos Medical (NYSE:AVNS) last released its earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. The company had revenue of $177.80 million during the quarter, compared to analyst estimates of $164.50 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Research analysts forecast that Avanos Medical will post 1.32 EPS for the current year.

Insider Activity at Avanos Medical

In other news, SVP Kerr Holbrook sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total transaction of $165,000.00. Following the transaction, the senior vice president owned 83,860 shares in the company, valued at approximately $922,460. This trade represents a 15.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds have recently bought and sold shares of AVNS. Versant Capital Management Inc raised its holdings in Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after buying an additional 894 shares in the last quarter. US Bancorp DE lifted its holdings in Avanos Medical by 7.7% in the 1st quarter. US Bancorp DE now owns 15,184 shares of the company’s stock worth $218,000 after purchasing an additional 1,091 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV boosted its position in Avanos Medical by 3.0% during the third quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock worth $500,000 after purchasing an additional 1,240 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Avanos Medical by 6.9% during the third quarter. Federated Hermes Inc. now owns 25,083 shares of the company’s stock valued at $290,000 after purchasing an additional 1,612 shares during the last quarter. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.